CycloZ Improves Hyperglycemia and Lipid Metabolism by Modulating Lysine Acetylation in KK-Ay Mice
Diabetes & Metabolism Journal · 2023
DOI: 10.4093/dmj.2022.0244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes & Metabolism Journal, 2023. Verfasst von Jongsu Jeon und 15 weiteren Autor:innen. Beteiligte Einrichtung: R&D Center, NovMetaPharma Co., Ltd., Seoul, Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hyperglycemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare.
Abstract (Originalsprache)
Background
CycloZ, a combination of cyclo-His-Pro and zinc, has anti-diabetic activity. However, its exact mode of action remains to be elucidated.
Methods
KK-Ay mice, a type 2 diabetes mellitus (T2DM) model, were administered CycloZ either as a preventive intervention, or as a therapy. Glycemic control was evaluated using the oral glucose tolerance test (OGTT), and glycosylated hemoglobin (HbA1c) levels. Liver and visceral adipose tissues (VATs) were used for histological evaluation, gene expression analysis, and protein expression analysis.
Results
CycloZ administration improved glycemic control in KK-Ay mice in both prophylactic and therapeutic studies. Lysine acetylation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, liver kinase B1, and nuclear factor-κB p65 was decreased in the liver and VATs in CycloZ-treated mice. In addition, CycloZ treatment improved mitochondrial function, lipid oxidation, and inflammation in the liver and VATs of mice. CycloZ treatment also increased the level of β-nicotinamide adenine dinucleotide (NAD+), which affected the activity of deacetylases, such as sirtuin 1 (Sirt1).
Conclusion
Our findings suggest that the beneficial effects of CycloZ on diabetes and obesity occur through increased NAD+ synthesis, which modulates Sirt1 deacetylase activity in the liver and VATs. Given that the mode of action of an NAD+ booster or Sirt1 deacetylase activator is different from that of traditional T2DM drugs, CycloZ would be considered a novel therapeutic option for the treatment of T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- R&D Center, NovMetaPharma Co., Ltd., Seoul, Korea.
- Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, Korea.
- Research Institute of Aging and Metabolism, Kyungpook National University, Daegu, Korea.
- Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.
- School of Life Science, Handong Global University, Pohang, Korea.
- Department of Medicine, Graduate School, Daegu Catholic University, Gyeongsan, Korea.
Förderung
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
Zitieren
APA
Jeon, J., Lee, D., Kim, B., Park, B. Y., Oh, C. J., Kim, M. J., Jeon, J. H., Lee, I. K., Park, O., Baek, S., Lim, C. W., Ryu, D., Fang, S., Auwerx, J., Kim, K. T., & Jung, H. Y. (2023). CycloZ Improves Hyperglycemia and Lipid Metabolism by Modulating Lysine Acetylation in KK-Ay Mice. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2022.0244
Vancouver
Jeon J, Lee D, Kim B, Park BY, Oh CJ, Kim MJ, et al. CycloZ Improves Hyperglycemia and Lipid Metabolism by Modulating Lysine Acetylation in KK-Ay Mice. Diabetes & Metabolism Journal. 2023. doi:10.4093/dmj.2022.0244
BibTeX
@article{Jeon2023,
author = {Jeon, Jongsu and Lee, Dohyun and Kim, Bobae and Park, Bo-Yoon and Oh, Chang Joo and Kim, Min-Ji and Jeon, Jae-Han and Lee, In-Kyu and Park, Onyu and Baek, Seoyeong and Lim, Chae Won and Ryu, Dongryeol and Fang, Sungsoon and Auwerx, Johan and Kim, Kyong-Tai and Jung, Hoe-Yune},
title = {CycloZ Improves Hyperglycemia and Lipid Metabolism by Modulating Lysine Acetylation in KK-Ay Mice},
journal = {Diabetes & Metabolism Journal},
year = {2023},
doi = {10.4093/dmj.2022.0244}
}
EUVIMED